Coxsackievirus B3 (CVB3)-induced myocarditis, initially considered a sole immune-mediated disease, also results from a direct CVB3-mediated injury of the cardiomyocytes. Mesenchymal stem cells (MSCs) have, besides immunomodulatory, also anti-apoptotic features. In view of clinical translation, we first analysed whether MSCs can be infected by CVB3. Next, we explored whether and how MSCs could reduce the direct CVB3-mediated cardiomyocyte injury and viral progeny release, in vitro, in the absence of immune cells. Finally, we investigated whether MSC application could improve murine acute CVB3-induced myocarditis.
Introduction
Myocarditis is a common inflammatory cardiomyopathy which can lead to a chronic impaired left ventricular (LV) function. Many different infectious agents have been considered the cause of viral myocarditis, including enteroviruses, adenovirus, cytomegalovirus, hepatitis C virus, parvovirus B19, and others. Among the most commonly identified infectious agents are the coxsackie B viruses (CVB), members of the enteroviral family. A direct CVB3-mediated injury of the cardiomyocytes in infected hearts 1, 2 as well as cardiac inflammation 3 underlies CVB3-induced viral myocarditis.
Under present pharmacological treatment, which is mainly focused on decreasing the activity of the neuroendocrine system, the prognosis against virus-induced inflammatory cardiomyopathy is not improved. This might be due to the lack of effects on the direct virus-induced components of the disorder. Therefore, different strategies, including gene therapeutic approaches and † These authors contributed equally. pharmaca directed at blocking viral replication or stimulating the anti-viral directed immune response, 4 are under investigation in experimental 5 and/or clinical studies. 6 There is accumulating experimental 2 and clinical support 7, 8 for the application of cellular transplantation as a strategy to improve myocardial function. Mesenchymal stem cells (MSCs) have anti-apoptotic, 9 anti-fibrotic, 10 and pro-angiogenic 11 features. They have the advantage over other stem cells that they are nonimmunogenic, enabling the use of allogeneic MSCs for clinical application. 8 Moreover, MSCs have immunomodulatory properties, 12 which make them an attractive cell source for the treatment of virus-induced inflammatory cardiomyopathy, given the importance of the inflammatory component in this disorder. Among others, MSCs suppress T cell responses, 13, 14 induce apoptosis of activated T cells, 15 and increase T regulatory cells. 16 Interferon-g (IFN-g) has been shown to play an important role in priming MSC-mediated immunoregulatory effects 12, 17 as well as in inducing nitric oxide (NO) production in MSCs. 18 On the other hand, NO exerts antiapoptotic effects on cardiomyocytes 19, 20 and has anti-viral properties. 21 Moreover, MSCs have been shown to exert their immunomodulatory effects in an NO-dependent manner. 12 The present study focuses at investigating whether MSCs are potential candidates for the treatment of acute CVB3-induced inflammatory cardiomyopathy. In view of clinical translation, the safety aspect whether MSCs can be infected by CVB3 is investigated. In addition, the study focuses at evaluating whether and how MSCs can (i) reduce the direct CVB3-mediated cardiomyocyte injury in vitro, and (ii) decrease cardiac apoptosis and improve LV function in an experimental model of murine acute CVB3-induced myocarditis. Furthermore, the role of NO and of IFN-g priming in the MSC-mediated protective effects is investigated.
Methods
For detailed methodology, please see Supplementary material online. Human adult MSCs were isolated from iliac crest bone marrow aspirates of normal male donors (n ¼ 6) after their written approval. Mesenchymal stem cells were characterized by flow cytometry analysis according to Binger et al. 22 To investigate whether MSCs can be infected with CVB3, MSCs were serum starved or exposed to CVB3 at a multiplication of infection (m.o.i.) of 5 for 1 h under serumstarvation conditions. Next, cell morphology, cell viability, and CVB3 RNA copy number were evaluated 4, 12, 24, and 48 h after serum starvation/infection via phase contrast pictures, MTS viability assay, and real-time PCR, respectively. Next, to determine whether MSCs can protect against direct CVB3-induced cardiomyocyte damage, MSCs were co-cultured with uninfected or CVB3-infected HL-1 cardiomyocytes at a ratio of 1 MSC to 10 HL-1. The effect of MSC supplementation on CVB3-induced HL-1 cardiomyocyte apoptosis, oxidative stress, virion progeny release, and intracellular virion production was determined via annexin V/7AAD flow cytometry and caspase 3/7 activity analysis, DCF flow cytometry, and plaque assay, respectively. To analyse whether the MSC-mediated effects were NO dependent, MSCs were pre-treated with nitro-L-argininmethylesterhydrochloride (L-NAME) for 24 h. To investigate whether MSCs require IFN-g to exert their protective effects, MSCs were co-cultured with uninfected or CVB3-infected HL-1 cells in the presence of 1 mg/mL of anti-murine IFN-g antibody. NO x and IFN-g levels in HL-1 monocultures as well as in co-cultures with MSCs were analysed. Furthermore, the effect of IFN-g supplementation on NO x production in uninfected or CVB3-infected MSCs was evaluated.
In vivo, 10 6 MSCs or phosphate buffered saline (PBS) was i.v. injected 23 in 6 -8-week-old C57BL/6 mice 1 day after i.p. infection with 5 × 10 5 plaque-forming units of CVB3 (Nancy strain). Controls received PBS instead of CVB3. Seven days after CVB3 infection, contractility parameters were analysed as described previously. 24 Left ventricular damage, apoptosis, and tumour necrosis factor-a (TNF-a) mRNA expression were determined via haematoxylin eosin staining, TUNEL staining, and real-time PCR, respectively. Furthermore, the effect of MSC application on cardiac mononuclear cell (MNC) proliferation/activation was evaluated via isolation of cardiac MNCs, followed by carboxyfluorescein succinimidyl ester-staining and flow cytometry. Finally, it was evaluated how MSCs reduce the proliferation of CVB3-induced CD42 and CD82 T cell proliferation via (co)-culture of carboxyfluorescein succinimidyl ester-labelled MNCs stimulated with inactivated CVB3, with or without MSCs (untreated or pretreated with L-NAME for 24 h) in the presence or absence of 1 mg/ mL of anti-murine IFN-g antibody, followed by CD4 and CD8 staining and flow cytometry. NO x and IFN-g levels in MNC monocultures as well as in co-cultures with MSCs were analysed.
Results

Mesenchymal stem cells cannot be infected by coxsackievirus B3
Human adult MSCs were isolated from iliac crest bone marrow aspirates of normal male donors (n ¼ 6) after their written approval. A representative picture of a flow cytometry analysis of MSC is shown in Supplementary material online, Figure S1 . To investigate whether MSCs can be infected with CVB3, whether replication of CVB3 takes place, and whether MSCs suffer from CVB3, a time-frame experiment was performed. Phase contrast pictures did not show any significant changes in cell morphology between serum-starved and CVB3-infected MSCs under serumstarvation conditions ( Figure 1A ). In line with this observation, no significant differences were found in MSC viability between postinfection and post-serum starvation at all time points ( Figure 1B) . Coxsackievirus B3 RNA copy number, expressed as CVB3 towards L32, decreased over time in MSCs, with 4.1-fold (P ¼ 0.057) and 7.2-fold (P ¼ 0.036) lower levels at 24 and 48 h postinfection vs. 4 h post-infection, respectively ( Figure 1C) . No plaques were detected on HeLa cells incubated with the medium collected from MSCs 24 h after CVB3 infection, not at dilutions 10 25 and 10 24 , neither at dilution 10 23 . In addition, the inability to infect MSCs with CVB3 was further underscored by the finding that the beneficial effects of MSCs were not impaired after CVB3 infection compared with serum starvation (Supplementary material online, Figure S2 ).
Mesenchymal stem cells reduce coxsackievirus B3-induced apoptosis
Coxsackievirus B3 targets cardiomyocytes, leading to cardiomyocyte apoptosis. 2 To investigate whether MSCs exert anti-apoptotic effects on CVB3-infected HL-1 cardiomyocytes, we co-cultured MSCs in the presence of CVB3-infected HL-1 and performed annexin V/7AAD FACS analysis. Phase contrast pictures showed that MSCs reduce the amount of CVB3-induced floating cells, indicative for necrotic cells (Figure 2A , upper panel). In addition, MSCs decreased the 4.2-fold (P ¼ 0.029) CVB3-induced HL-1 apoptosis to levels not significantly different from non-infected cells (Figure 2A , middle and lower panels). Mesenchymal stem cells have been shown to exert immunomodulatory effects in an NO-dependent manner and to require IFN-g priming. 12 We evaluated whether these underlying mechanisms could be extrapolated to the MSC-mediated protective effects in the context of CVB3-infected HL-1 cells. Therefore, MSCs were pre-treated with L-NAME or co-cultured with CVB3-infected HL-1 cells in the presence of an anti-mouse IFN-g-neutralizing antibody. Under these conditions, the anti-apoptotic MSC-mediated effects were abrogated. Next, we analysed whether the MSC-mediated reduction in HL-1 apoptosis was associated with decreased caspase 3/7 activity. Supplementation of MSCs declined the CVB3-induced caspase 3/7 activity by 1.4-fold (P , 0.0008). This effect was abrogated when MSCs were pre-treated with L-NAME and was less pronounced in the presence of an anti-mouse IFN-g antibody ( Figure 2B) . NO x levels were not increased in the medium of HL-1 and MSC co-cultures compared with HL-1 monocultures, suggesting that at a ratio of 1 MSC to 10 HL-1 cells, the increase in NO is not detectable (Supplementary material online, Figure S3A ). Mesenchymal stem cell supplementation did not affect murine IFN-g levels of HL-1 cells (Supplementary material online, Figure S3B ).
Mesenchymal stem cells reduce coxsackievirus B3-induced oxidative stress in HL-1 cardiomyocytes
Given the importance of the intracellular oxidation status in the pathogenesis of CVB3 infections, 25 we investigated whether MSCs exert anti-oxidative effects on CVB3-infected HL-1 cells. Therefore, we analysed the presence of ROS in MSC-HL-1 co-cultures by CM-H 2 DCFDA flow cytometry. To distinguish the presence of ROS in HL-1 cells or MSCs in the MSC-HL-1 co-cultures, HL-1 cells were pre-labelled with the fluorescence dye Dil before plating. Flow cytometry analysis showed that CVB3 induced ROS production in HL-1 cells by 6.3-fold (P ¼ 0.0076) ( Figure 3) , whereas MSCs reduced the increased ROS production by 5.1-fold (P ¼ 0.029) to levels not significantly different from non-infected controls. The anti-oxidative effects of MSCs were abrogated when MSCs were pre-treated with L-NAME or co-cultured in the presence of antimouse IFN-g-neutralizing antibody (Figure 3 ).
Mesenchymal stem cells reduce viral progeny release and intracellular viral particle production in HL-1 cardiomyocytes
We next evaluated whether the anti-apoptotic and anti-oxidative effects of MSCs on CVB3-infected HL-1 cells were paralleled with a reduction in viral progeny release. Therefore, medium from co-culture experiments was collected and plaque assay was performed. CAPs reduced the viral progeny release by 5.1-fold (P ¼ 0.007), an effect which was blunted in the presence of L-NAME and by blocking murine IFN-g ( Figure 4A ). Further analysis demonstrated that besides reducing the release of CVB3 virions, MSCs also decreased the production of intracellular CVB3 particles in an NO-dependent manner and required priming via IFN-g ( Figure 4B ).
Interferon-g increases nitric oxide in coxsackievirus B3-infected mesenchymal stem cells
Recently, Oh et al. 18 demonstrated that IFN-g is critical for NO production by MSCs. Since our data indicate that MSCs exert their protective effects on CVB3-infected HL-1 cells in an NO-dependent manner and require IFN-g, we next investigated whether the concentration of IFN-g present in the co-culture of HL-1 cells with MSCs can lead to NO induction in MSCs. Supplementation of murine IFN-g to non-infected MSCs did not increase NO production, whereas CVB3 infection combined with murine IFN-g administration raised NO production by 1.2-fold (P ¼ 0.031) vs. non-infected MSCs (Supplementary material online, Figure S4 ).
Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis
After evaluating in vitro whether and how MSCs can reduce the direct CVB3-induced cardiomyocyte damage, we finally investigated whether MSC application could improve murine acute CVB3-induced myocarditis in vivo. Cardiac contractility and relaxation were significantly ameliorated in MSC-treated compared with PBS-injected CVB3-infected mice, as indicated by a 1.5-fold (P ¼ 0.0002) and 1.7-fold (P ¼ 0.001) improvement in the contractility parameters dP/dt max and dP/dt min , respectively ( Figure 5 ). This was associated with a reduction in cardiomyocyte necrosis and fibrosis, as indicated by haematoxylin and eosin staining ( Figure 6A ). Furthermore, MSC application decreased the CVB3-induced cardiac apoptosis ( Figure 6B) and LV TNF-a mRNA expression ( Figure 6C ) by 3.2-fold (P ¼ 0.018) and 3.2-fold (P , 0.0001), respectively.
Mesenchymal stem cells reduce cardiac mononuclear cell activity in coxsackievirus B3-infected mice
Finally, we analysed whether MSC application could reduce the activity of cardiac MNCs in murine acute CVB3-induced myocarditis. Therefore, cardiac MNC isolated from control and CVB3-infected mice, injected with PBS or MSCs, was carboxyfluorescein succinimidyl ester-labelled and cultured for 72 h in the presence or absence of inactivated CVB3, followed by flow cytometry analysis. The amount of peaks, indicative for cell proliferation, was reduced in cardiac MNCs isolated from CVB3-infected mice receiving MSCs compared with PBS-injected CVB3-infected mice, under unstimulated as well as stimulated conditions ( Figure 7A) . To further evaluate how MSCs exert these antiproliferative effects, MNCs were isolated from the spleen from control and CVB3-infected mice, carboxyfluorescein succinimidyl ester-labelled, and next cultured with or without untreated or L-NAME-treated MSCs, or with MSCs in the presence or absence of 1 mg/mL of IFN-g antibody. Supplementation of MSCs to MNCs at a ratio of 1 to 10 reduced the inactivated CVB3-stimulated division index of CD42 and CD82 T cells from CVB3-infected mice by 2.5-fold (P ¼ 0.029) and 2.5-fold (P ¼ 0.029), respectively. This effect was less pronounced or abrogated when MSCs were pretreated with L-NAME or co-cultured with MNCs in the presence of an IFN-g antibody ( Figure 7B ). Similar to HL-1-MSC co-cultures, no increase in NO x levels could be observed in MNC-MSC co-cultures compared with MNC monocultures, suggesting that at a ratio of 1 MSC to 10 MNCs, the increase in NO is not detectable (Supplementary material online, Figure S5A ). Interferon-g levels in the medium of MNCs derived from CVB3-infected mice were significantly induced upon stimulation with inactivated CVB3 and decreased when MSCs were supplemented (Supplementary material online, Figure S5B ).
Discussion
The findings of the present study are that MSCs (i) cannot be infected by CVB3; (ii) reduce direct CVB3-induced cardiomyocyte injury in an NO-dependent way and require priming by IFN-g, and (iii) improve experimental murine acute CVB3-induced myocarditis.
Coxsackievirus B3-induced viral myocarditis, initially considered a sole immune-mediated disease, 3 also results from a direct CVB3-mediated injury of the cardiomyocytes in infected hearts. 1, 2 Besides its immunomodulatory effects, MSCs have also been shown to have anti-apoptotic features. The aim of our study was to investigate whether MSCs are potential candidates for the treatment of acute CVB3-induced inflammatory cardiomyopathy. In detail, we analysed whether and how MSCs can (i) reduce the direct CVB3-mediated cardiomyocyte injury in vitro, and (ii) decrease cardiac apoptosis and improve LV function in an experimental model of murine acute CVB3-induced myocarditis. Furthermore, the role of NO and IFN-g priming in the MSC-mediated protective effects was investigated.
In view of clinical translation, it is a prerequisite that no replication of CVB3 can take place in MSCs or in any other cell used for (cardiac) cell therapy. We could demonstrate that MSCs did not suffer from CVB3 infection and that CVB3 copy number decreased over time, suggesting that CVB3 did not replicate. Moreover, no viral progeny release occurred. These findings are in line with the described limited expression of the coxsackievirus adenovirus receptor, which is a critical determinant for cellular uptake and pathogenesis of CVB3, 26 on MSCs. 27 Furthermore, CVB3 infection did not alter the beneficial effects of MSCs, suggesting that the functionality of MSCs upon application in patients with acute CVB3 infection would not be impaired. Recent studies show that the protective effects of bone marrow-derived MSCs from patients with co-morbidities 28, 29 are less pronounced compared with those of MSCs from healthy donors. The investigation of the characteristics of MSCs from patients with virus-induced inflammatory cardiomyopathy was beyond the scope of this study. The successful use of allogeneic MSCs in clinical studies for the treatment of noncardiac 30 as well as cardiac 8 disorders provides consisting support to use allogeneic instead of autologous bone marrow-derived MSCs for the treatment of virus-induced inflammatory cardiomyopathy.
Apoptosis plays an important role in the CVB3 life cycle by facilitating viral progeny release and propagation. 31 CVB3 also induces ROS production, which takes place secondary to virus-induced apoptosis, following caspase cleavage 32 and can contribute to the activation of stress-activated protein kinases, which in turn are required for viral replication and progeny release. 33 In our study, we found that MSCs significantly reduced apoptosis and ROS production in HL-1 cells. We suggest that the MSC-mediated decrease in caspase activity underlies the reduction in ROS. The intracellular oxidation status has been implicated in the pathogenesis of CVB3 infections 25 by which the ROS-mediated release of host cell nuclear transcription factor-k-B results in increased viral replication. Our data indicate that MSCs reduce the intracellular viral production, suggesting that the MSC-mediated decrease in ROS production underlies the reduction in viral replication. Furthermore, MSCs impaired the viral progeny release. Since the intracellular virion particle production affects the amount of viral particle release, on the one hand, and the liberation of viral particles requires apoptosis of infected cells, 31 on the other hand, we suggest that the MSC-mediated decline in cardiomyocyte ROS production and apoptosis underlies the attenuation in viral progeny release.
Moreover, we could demonstrate that the anti-apoptotic and anti-oxidative features of MSCs and their effect on viral progeny release and viral production were abrogated when MSCs were pre-treated with the iNOS inhibitor L-NAME, suggesting an NO-dependent mechanism. This observation is supported by the Next, carboxyfluorescein succinimidyl ester-labelled mononuclear cells were directly cultured, in the presence or absence of inactivated CVB3, with or without MSCs (untreated or 24 h pre-treated with L-NAME), in the presence or absence of 1 mg/mL of anti-murine interferon-g (IFN-g) antibody for 72 h. Then, cells were stained with monoclonal anti-CD4 or anti-CD8 antibodies, followed by flow cytometry and analysis with FlowJo 8.7. software. Bar graphs represent the division index of CD42 (upper panel) and of CD82 T cells (lower panel) with n ¼ 4/group. evidence that stem cells conduct their cardioprotective effects in an NO-dependent manner, 34 that NO exerts anti-apoptotic effects on cardiomyocytes, 19, 20 and that NO has anti-viral properties. 21, 35 In detail, NO donors have been shown to reduce viral replication 35 and to decrease signs of myocarditis in CVB3-infected mice. 20 Furthermore, the MSC-mediated protective effects were less pronounced in the presence of a murine anti-IFN-g antibody, suggesting that MSCs require IFN-g priming to exert their antiapoptotic, anti-oxidative, and anti-viral features. This hypothesis is supported by the finding that IFN-g is crucial for priming MSCs to conduct their immunomodulatory effects. 12, 17 Furthermore, Oh et al. 18 recently demonstrated that IFN-g is critical for NO production by MSCs. We could show that supplementation of IFN-g to CVB3-infected MSCs increased NO vs. non-infected MSC controls. This suggests that in the context of CVB3 and upon activation with IFN-g, MSCs produce NO via which they exert their anti-apoptotic and anti-oxidative effects, leading to a decrease in viral progeny release and viral production.
Besides priming MSCs, IFN-g has been shown to reduce CVB3 replication and CVB3-induced cytopathogenicity, in part via inducing the release of NO by macrophages. 36, 37 However, we can exclude that the worsened condition of CVB3-infected HL-1 supplemented with an IFN-g antibody and MSCs was due to the reduced presence of unbound IFN-g, since supplementation of an IFN-g antibody alone by CVB3 infection was not associated with an impaired condition of HL1 cells (data not shown).
In vivo, we demonstrated that MSC application resulted in an improvement in contractility, which was paralleled with an impaired cardiac damage and cardiac apoptosis, reduced TNF-a mRNA levels, and cardiac MNC activation. The pathogenesis of CVB3-induced myocarditis is besides a direct CVB3-induced injury also characterized by the infiltration of inflammatory cells, by which the infiltration of T cells coincides with the most severe acute pathological damage in the myocardium. 38 The importance of T cells in the severity and development of myocarditis follows from the marked reduction in myocardial damage in CVB3-infected mice treated with a monoclonal antibody against total T cells. 39 We foresee that the reduced cardiac injury and apoptosis in CVB3-infected mice receiving MSCs compared with PBS are due to the direct anti-apoptotic and anti-viral effects of MSCs, as shown in vitro, and to MSC-mediated immunomodulatory effects. Injection of MSCs resulted in a decrease in cardiac mRNA levels of the pro-inflammatory cytokine TNF-a, which is known to induce cardiomyocyte apoptosis. 40 Furthermore, MSC injection reduced the activity of cardiac MNCs from CVB3-infected mice. Since T cells are crucial for the severity of cardiac damage in CVB3-induced myocarditis, 39 we suggest that the impaired cardiac MNC activity contributed to the decreased cardiac damage and apoptosis. In agreement with Ren et al., 12 we demonstrated that the MSC-mediated reduction in CVB3-induced CD42 and CD82 T cell proliferation was NO dependent and required IFN-g priming. The importance of IFN-g priming for the functionality of MSCs, on the one hand, and the increased cardiac IFN-g levels in acute CVB3-induced myocarditis, on the other hand, 41 support the hypothesis that MSCs will exert their protective effects in the cardiac inflammatory environment by acute CVB3-induced myocarditis.
In conclusion, our data suggest that MSCs have the potential to be used to treat acute CVB3-induced inflammatory cardiomyopathy since MSCs (i) cannot be infected with CVB3, (ii) have antiapoptotic and anti-viral effects, and (iii) improve cardiac function in an experimental model of acute CVB3-induced myocarditis. However, further investigation is still required to assess the potential of MSCs for the treatment of chronic CVB3-induced inflammatory cardiomyopathy.
